Does pioglitazone prevent macrovascular events in patients with type 2 diabetes?

Hiralal, Rajesh; Koo, Karen K. Y.; Gerstein, Hertzel C.
April 2006
CMAJ: Canadian Medical Association Journal;4/11/2006, Vol. 174 Issue 8, p1090
Academic Journal
The article discusses research being done on the use of pioglitazone to prevent macrovascular events in patients with type 2 diabetes. With reference to a study by J. A. Dormandy et al, published in a 2005 issue of the journal "Lancet." Most patients with type 2 diabetes have a myriad of other metabolic and vascular abnormalities. The association of these metabolic disturbances with macrovascular disease is stated. In addition, this article assesses the effectiveness of the drug.


Related Articles

  • Prevalence of the Metabolic Syndrome and Its Components. Ilanne-Parikka, Pirjo; Eriksson, Johan G.; Lindström, Jaana; Hämäläinen, Helena; Keinänen-Kiukaanniemi, Sirkka; Laakso, Mauri; Louheranta, Anne; Mannelin, Marjo; Rastas, Merja; Salminen, Virpi; Aunola, Sirkka; Sundvall, Jouko; Valle, Timo; Lahtela, Jorma; Uusitupa, Matti; Tuomilehto, Jaakko // Diabetes Care;Sep2004, Vol. 27 Issue 9, p2135 

    Presents the study "Prevalence of the Metabolic Syndrome and Its Components." Statistics on the prevalence of type 2 diabetes worldwide; Risk facing subjects with abnormal glucose metabolism; Definition of the metabolic syndrome and its components; Results of the study.

  • Insulin Resistance And Syndrome X.  // Health & Stress;2002, Issue 5, p4 

    Reports on the link between insulin resistance and metabolic syndrome X. Symptoms and etiology of the syndrome; Prevalence of insulin resistance in patients with Type 2 diabetes; Factors mediating the complications of non-insulin dependent patients.

  • Low Production Capacity of Interleukin-10 Associates With the Metabolic Syndrome and Type 2 Diabetes.  // Diabetes;Apr2002, Vol. 51 Issue 4, p1088 

    Examines the association between low production capacity of interleukin-10 and the metabolic syndrome and type 2 diabetes in aged in Leiden. Manifestations of host response; Production capacity of the anti-inflammatory cytokine; Role of cytokines in the development of the metabolic syndrome.

  • The Insulin-sensitizing Role of the Fat Derived Hormone Adiponectin. Heilbronn, L.K.; Smith, S.R.; Ravussin, E. // Current Pharmaceutical Design;Jul2003, Vol. 9 Issue 17, p1411 

    Adiponectin is an insulin-sensitizing hormone whose blood concentration is reduced in obesity and type 2 diabetes. Administration of recombinant adiponectin in rodents increases glucose uptake and increases fat oxidation in muscle, reduces fatty acid uptake and hepatic glucose production in...

  • Ezetimibe, a Potent Cholesterol Absorption Inhibitor, Normalizes Combined Dyslipidemia in Obese Hyperinsulinemic Hamsters. van Heek, Margaret; Austin, Theodore M.; Farley, Constance; Cook, John A.; Tetzloff, Glen G.; Davis, Harry R. // Diabetes;Jun2001, Vol. 50 Issue 6, p1330 

    Examines the role of ezetimibe as a cholesterol absorption inhibitor in normalizing a combined dyslipidemia in obese hyperinsulenemic hamsters. Increase in the ratio of HDL TO LDL after the addition of ezetimide; Elimination of cholesteryl in the liver; Benefits of ezetimibe in type 2 diabetes.

  • Controversias en el diagnóstico del síndrome metabólico en pob aciones pediátr cas. Arjona-Villicañ, Ruy David; Gómez-Díiaz, Rita Angélica; Aguilar-Salinas, Carlos Alberto // Boletin Medico del Hospital Infantil de Mexico;nov/dic2008, Vol. 65 Issue 6, p488 

    The metabolic syndrome is a clinical concept which incorporates the phenotypic expression of intra-abdominal fat and insulin resistance under a single diagnosis. The main end points of the metabolic syndrome are well known, namely type 2 diabetes mellitus and atherosclerosis. The prevalence of...

  • Diabetes: Magnitude and Mechanisms. Fowler, Michael J. // Clinical Diabetes;Winter2010, Vol. 28 Issue 1, p42 

    The article discusses several aspects of diabetes which is becoming an issue of concern in the U.S. The American Diabetes Association (ADA) defines diabetes as a metabolic disease that cause hyperglycemia. It mentions various categories of diabetes which include type 1 diabetes, type 2 diabetes,...

  • Type 2 Diabetes in the Young: The Evolving Epidemic. Alberti, George; Zimmet, Paul; Shaw, Jonathan; Bloomgarden, Zachary; Kaufman, Francine; Silink, Martin // Diabetes Care;Jul2004, Vol. 27 Issue 7, p1798 

    Cites key findings from a consensus workshop on type 2 diabetes in the young staged by the International Diabetes Foundation in 2003. Review of the epidemiology, pathophysiology, management and implications of the rising prevalence of type 2 diabetes in young people; Overall global prevalence of...

  • CITATIONS AND CLINICIANS' NOTES: EPIDEMIOLOGY.  // Current Medical Literature: Pediatrics;2004, Vol. 17 Issue 3, p65 

    Presents abstracts of several studies on pediatrics. "First UK Survey of Paediatric Type 2 Diabetes and MODY," by S. Ehtisham, A. T. Hattersley and D. B. Dunger; "Mass Screening for Coeliac Disease Using Antihuman Transglutaminase Antibody Assay," by A. Tommasini, T. Not and V. Kiren; "Higher...

  • 2. Definition and classification of diabetes mellitus.  // Journal of Endocrinology, Metabolism & Diabetes of South Africa;Jun2012, Vol. 17 Issue 2, pS5 

    The article discusses the different classifications of diabetes mellitus, a metabolic disorder which is characterised by chronic hyperglycaemia and disturbances of fat, carbohydrate and protein metabolism. The clinical stages of diabetes include normoglycaemia, impaired glucose tolerance (IGT)...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics